Neuropsychological Systems and Clinical Investigation

Knowledge Check and Foundational Concepts

• Peripheral Neuropathy: Contrary to the misconception that it only affects motor function, peripheral neuropathy involves both motor and sensory disruptions.
• Beta Blockers: These medications, when used in neurological or anxiety conditions, do not act by increasing parasympathetic activity; rather, they serve to block sympathetic (adrenergic) activity.
• Psychotropic Medications: It is a critical clinical rule that all psychotropic medications require consistent monitoring for potential adverse effects.
• Side Effect Management: If a patient reports early side effects from a psychotropic medication, treatment should not always be stopped immediately. Instead, a clinical assessment is required to determine if the effects are transient or if the dosage needs adjustment.
• Treatment Adherence: Factors such as social stigma and the health literacy of the patient significantly influence their adherence to mental health treatment plans.

Physiology Mapping and Homeostasis

• Understanding Normal Function: Mastery of a system's physiological functions is the essential prerequisite for analyzing homeostatic disruptions and the progression of disease.
• Key Regulatory Variables: In any body system, specific variables must be maintained within a narrow range to ensure homeostasis. Coordination occurs through various mechanisms: neural, hormonal, or mechanical.
• Criticality and Survival: Identifying which functions are most critical for survival and clinical relevance is a core competency for healthcare professionals.
• Feedback Mechanisms: Negative and positive feedback loops are the primary tools used by organs and structures to coordinate regulation.

Clinical Investigation Case Study: Round 1 - Initial Presentation

• Patient Overview:   - Age: $32$ years old   - Sex: Female   - Occupation: High school teacher   - Relevant Background: Recent relationship breakdown (8 months ago). No significant past history and no recreational drug use.
• Presenting Concern: Chronic low mood and anxiety negatively impacting occupational and social functioning for a duration of 6 months.
• Reported Symptoms:   - Persistent low mood for most of the day.   - Anhedonia (loss of interest in previously enjoyable activities).   - Sleep disturbances, specifically early morning waking and poor quality of sleep.   - Reduced appetite resulting in a significant $3\,kg$ weight loss.
• Clinical Observations:   - Blood Pressure ($BP$): $122/78\,mmHg$   - Heart Rate ($HR$): $86\,bpm$   - Body Mass Index ($BMI$): $23$
• Homeostatic Assessment: The primary disruption appears to be a failure of emotional, sleep, and appetite regulation. This may represent progressive deterioration or a failure of compensatory stress-response mechanisms.

Round 2: Additional Findings and Mechanistic Building

• Psychometric Assessment Results:   - Patient Health Questionnaire-9 ($PHQ\text{-}9$): Score of $18$, indicating moderate to severe depression.   - Generalized Anxiety Disorder-7 ($GAD\text{-}7$): Score of $14$, indicating moderate anxiety.
• Laboratory Investigation Results:   - Thyroid function: Normal.   - Full Blood Count ($FBC$) and Electrolytes: Normal.
• Mental State Examination ($MSE$):   - Affect: Observed as depressed.   - Psychomotor Activity: Slowed (psychomotor retardation).   - Cognition: Impaired concentration.   - Psychosis: None present.   - Insight: Intact.
• Mechanistic Pathway: Chronic stress or initial triggers ($A$) lead to physiological changes such as neurotransmitter depletion or $HPA$ axis dysregulation ($B$), which eventually results in the clinical presentation of depression and anxiety ($C$).

Round 3: Therapeutic Selection and Targets

• Current Medications: The patient is currently taking a Combined Oral Contraceptive Pill ($COCP$).
• Proposed Therapy Options:   - Referral for Cognitive Behavioural Therapy ($CBT$).   - Sertraline: Initiated at $25\,mg$ daily for $1$ week, then increased to $50\,mg$ daily.   - Propranolol: $10\,mg$ PRN (as required) for somatic anxiety symptoms.
• Therapy Rationale: Therapies like $SSRIs$ (Sertraline) work by inhibiting the reuptake of serotonin, thereby increasing its availability in the synaptic cleft to help restore serotonergic tone and mood regulation.

Round 4: Risk Radar and Clinical Follow-Up

• 1-Week Follow-Up Observations:   - The patient reports increased anxiety and restlessness.   - Mild nausea is present.   - Patient Perspective: Worried that the medication is exacerbating the condition and concerned about long-term side effects.
• Identified Risks and Precautions:   - Contraindications/Precautions: Risk of increased suicidal ideation or worsening anxiety during the initiation phase of $SSRIs$.   - Adverse Effects: Nausea and restlessness are common early-stage side effects.   - Monitoring Requirements: Frequent assessment of mood and safety during the first several weeks of treatment.

Round 5: Holistic Management and Broader Considerations

• Social and Environmental Context:   - High occupational stress from managing classrooms and high performance demands.   - Prevailing social withdrawal.
• Patient Perspective on Stigma: The patient expresses concern regarding the stigma of taking medication but remains willing to engage in psychological therapy.
• Multi-Disciplinary Management: Effective management requires an integrated approach involving GPs for monitoring, psychologists for $CBT$, and workplace support for stress management.

Course Learning Objective ($CLO$) Links

• $CLO\,1$ (Disruptions to Homeostasis): Dysregulation of the monoamine neurotransmission and the stress-response system ($HPA$ axis) disrupts emotional, sleep, appetite, and anxiety homeostasis.
• $CLO\,2$ (Underlying Pathological Mechanisms): Chronic stress leads to prolonged cortisol elevation, reduced serotonergic tone, and impaired prefrontal-limbic regulation.
• $CLO\,3$ (Core Pharmacological Concepts): Sertraline increases synaptic serotonin via reuptake inhibition; clinical benefit relies on downstream receptor adaptation and neuroplasticity, explaining the therapeutic lag.
• $CLO\,4$ (Major Drug Classes): $SSRIs$ target mood/anxiety; Propranolol acts via $\beta$-adrenergic blockade to reduce somatic symptoms. Monitoring for early adverse effects is essential.
• $CLO\,5$ (Interprofessional Collaboration): Management must integrate medical monitoring, psychological intervention, patient education, and workplace support.

Assessment A1 Part 2: Educational Pamphlet

• Task Description: Create a scientifically accurate, accessible pamphlet for a non-expert audience explaining a medical disorder and its pharmacological treatment.
• Learning Outcomes: Translating pathophysiology into patient-friendly language, applying pharmacokinetics ($PK$) and pharmacodynamics ($PD$), and ensuring cultural safety in an Australian context.
• Submission Components: Four written sections ($300\text{--}400$ words each) in Cadmus and a single-page pamphlet image using $CC$-licensed/royalty-free images.
• Approved Disorders and Treatments (Local Practice Alignment):   - Cardiovascular Disease ($CVD$): Antiplatelet Therapy.   - Diabetes Mellitus: Metformin Therapy.   - Osteoporosis: Bisphosphonate Therapy.   - Depression: $SSRI$ Therapy.   - Neurodivergence (e.g., $ADHD$): Stimulant Therapy.   - Vertigo: Vestibular Suppressant Therapy.   - Autoimmune Disease: Biologic ($TNF$ Inhibitor) Therapy.   - Chronic Musculoskeletal Pain: $NSAID$ Therapy.   - Gastro-oesophageal Reflux Disease ($GORD$): Proton Pump Inhibitor ($PPI$) Therapy.
• Source Requirements: At least $2\text{--}3$ recent, scientifically credible Australian or peer-reviewed sources.

Course Administration and Communication

• Course Coordinator: Dr. Anna Chruscik.
• Efficiency Protocols: Students must read announcements and check discussion forums before emailing. Responses may take several business days given the cohort size of approximately $500$ students.
• Ethics Approval: $ETH2025\text{-}0313$.